Inquis Medical, an innovator in advanced thrombectomy systems, today announced the successful closure of its oversubscribed $40 million Series B financing round. The round was led by Marshall Wace, a globally renowned investment firm, with strong support from existing investors including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond. This new funding will fuel Inquis Medical’s growth as it advances its cutting-edge technologies and prepares for the commercialization of its products.
Inquis Medical, a clinical-stage medical device company focused on next-generation thrombectomy systems, has successfully closed its $40 million Series B financing round. This oversubscribed round was led by Marshall Wace, a prominent global investment firm, with strong participation from existing investors including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond. The funding will accelerate the development and commercialization of Inquis Medical’s innovative technologies.
The company’s flagship product, the Aventus Precision Thrombectomy System™, features proprietary tissue-sensing technology that provides real-time insights into the tissue composition in contact with the device. This cutting-edge system enhances precision and control during thrombectomy procedures, setting a new standard for what current systems can achieve.
Earlier this year, Inquis Medical received FDA 510(k) clearance for both its Aventus Thrombectomy System™ and its blood return system for peripheral indications. The company is also nearing the completion of enrollment in its FDA Investigational Device Exemption (IDE) pivotal clinical study, which targets patients with pulmonary embolism (PE).
“We are thrilled to have successfully secured Series B funding. This is a strong validation of the confidence our investors have in our mission and the potential impact of our innovations,” said Vahid Saadat, Co-CEO and Co-Founder of Inquis Medical.
Mojgan Saadat, Co-CEO and Co-Founder, added, “This substantial investment from Marshall Wace, along with continued support from our existing investors, underscores the belief in our technology and our team. We are excited to take the next steps in enhancing patient care by empowering physicians with our unique, precision-driven technology.”
As part of the Series B financing, Dr. Andrew D. Goldberg, a portfolio manager at Marshall Wace, has joined Inquis Medical’s Board of Directors.
This funding marks a significant milestone in Inquis Medical’s development, enabling the company to complete its pivotal IDE trial, prepare for the commercial launch of the Aventus Thrombectomy System in 2025, and continue advancing its proprietary tissue-sensing platform.
Venous thromboembolism (VTE) affects up to 900,000 people annually in the U.S., with over 50% of deep vein thrombosis cases leading to pulmonary embolism (PE), the third leading cause of cardiovascular death. Current thrombectomy procedures often face challenges like significant blood loss and inefficiencies. Inquis Medical’s innovations are designed to address these issues and improve patient outcomes by offering more effective, safer alternatives.
The strong backing from Marshall Wace and other investors underscores the growing recognition of Inquis Medical’s promising technology and its potential to transform the thrombectomy field.
About Inquis Medical
Inquis Medical is a clinical-stage medical device company focused on developing next-generation thrombectomy technologies for peripheral vascular conditions. Founded in 2020, the company’s mission is to improve the precision, control, and efficiency of thrombectomy procedures while reducing blood loss. Inquis Medical’s leadership team brings over three decades of experience in the development, launch, and commercialization of medical devices that address critical unmet clinical needs.
